DURHAM – BioCryst Pharmaceuticals (BCRX) on Thursday reported a loss of $2.6 million in its fourth quarter. On a per-share basis, the Durham, North Carolina-based company said it had a loss of 2 cents. But the results topped Wall Street expectations.
The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 25 cents per share.
“2020 is off to a strong start, with NDAs accepted and approvals lined up later this year in the U.S. and Japan, and continued progress with our oral Factor D program as we approach proof of concept data in PNH patients in the second quarter of the year,” said Jon Stonehouse, president and chief executive officer of BioCryst.
“We are hearing increasing excitement from both HAE patients and physicians about the availability of an oral option to manage their disease, and we are attracting outstanding commercial talent to bring this new medicine to patients,”
The drugmaker posted revenue of $39.7 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $12 million.
For the year, the company reported that its loss widened to $108.9 million, or 94 cents per share. Revenue was reported as $48.8 million.
The company’s shares closed at $3.51. A year ago, they were trading at $8.79.
